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Previously, we demonstrated in cultured dorsal root
ganglion neurons that, in the presence of b-migrating
very low density lipoproteins (b-VLDL), apolipoprotein
(apo) E4, but not apoE3, suppresses neurite outgrowth.
In the current studies, murine neuroblastoma cells
(Neuro-2a) were stably transfected with human apoE3
or apoE4 cDNA, and the effect on neurite outgrowth was
examined. The stably transfected cells secreted nano-
gram quantities of apoE (44–89 ng/mg of cell protein in
48 h). In the absence of lipoproteins, neurite outgrowth
was similar in the apoE3- and apoE4-secreting cells. The
apoE4-secreting cells, when incubated with b-VLDL,
VLDL, cerebrospinal fluid lipoproteins (d < 1.21 g/ml),
or with triglyceride/phospholipid (2.7:1 (w/w)) emul-
sions, showed a reduction in the number of neurites/cell,
a decrease in neurite branching, and an inhibition of
neurite extension, whereas in the apoE3-secreting cells
in the presence of a lipid source, neurite extension was
increased. Uptake of b-VLDL occurred to a similar ex-
tent in both the apoE3- and apoE4-secreting cells. With
low density lipoproteins or with dimyristoylphosphati-
dylcholine emulsions, either alone or complexed with
cholesterol, no differential effect on neurite outgrowth
was observed. A slight differential effect was observed
with apoE-containing high density lipoproteins. The dif-
ferential effect of apoE3 and apoE4 in the presence of
b-VLDL was blocked by incubation of the cells with he-
parinase and chlorate, with lactoferrin, or with recep-
tor-associated protein, all of which prevent the uptake
of lipoproteins by the low density lipoprotein receptor-
related protein (LRP). The data suggest that the se-
creted and/or cell surface-bound apoE interact with the
lipoproteins and facilitate their internalization via the
heparan sulfate proteoglycan-LRP pathway. The mech-
anism by which apoE3 and apoE4 exert differential ef-
fects on neurite outgrowth remains speculative. How-
ever, the data suggest that apoE4, which has been shown
to be associated with late onset familial and sporadic
Alzheimer’s disease, may inhibit neuronal remodeling
and contribute to the progression of the disease.
Apolipoprotein (apo)1 E, a 34-kDa protein coded for by a gene
on chromosome 19, plays a prominent role in the transport and
metabolism of plasma cholesterol and triglyceride through its
ability to interact with the low density lipoprotein (LDL) re-
ceptor and the LDL receptor-related protein (LRP) (1, 2). Apo-
lipoprotein E also may play an important role in the redistri-
bution of lipids within the central nervous system (3). More
than three-fourths of the apoE in the plasma is synthesized by
the liver (4), whereas apoE in cerebrospinal fluid (CSF) is
produced primarily by astrocytes within the brain (5–7). Three
common isoforms of apoE, distinguished by differing mobility
on isoelectric focusing gels, differ in amino acids at positions
112 and 158 (1). The most common isoform, apoE3, has cysteine
at position 112 and arginine at 158, whereas apoE2 has cys-
teine at both positions, and apoE4 has arginine at both. The
isoforms are encoded by three alleles at the same gene locus.
Apolipoprotein E4 has recently been shown to be associated
with Alzheimer’s disease (AD) (8–18).
Late onset familial AD is linked to the proximal long arm
of chromosome 19 (10), which contains the apoE locus (1).
Saunders and co-workers at Duke University (14) were the first
to demonstrate that the apoE4 allele is associated with both
late onset familial and sporadic forms of AD, which together
account for 90% of cases (14). The association of apoE4 with AD
has been confirmed by several groups (9, 12, 19, 20). Whereas
the allele frequency for apoE4 is ;0.143 in the general popu-
lation (21), it is 0.36–0.57 in various populations of patients
with late onset AD (9, 12, 14, 19, 20). In families with late onset
AD, the risk for AD increases from 20 to 90%, and the mean age
of onset decreases from 84 to 68 years with an increasing
number of apoE4 alleles. Homozygosity for apoE4 is virtually
certain to result in AD by age 80 (11). The defining neuropatho-
logical features of AD are the presence of extracellular deposits
of b-amyloid in the cerebral cortex and vascular amyloid
around blood vessels as well as intracellular deposits of hyper-
phosphorylated t in the form of neurofibrillary tangles in
neurons of the cortex, hippocampus, and amygdala (22).
Apolipoprotein E is associated with both the senile plaques
and neurofibrillary tangles present in the brains of AD
patients (10).
The mechanism by which apoE4 is related to AD is unknown
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and could involve a direct effect of apoE on neurons. We there-
fore examined the effect of apoE3 and apoE4 on neurons in
vitro. When fetal rabbit dorsal root ganglion (DRG) neurons
were incubated with b-migrating very low density lipoproteins
(b-VLDL), which are rich in apoE and cholesterol, neurite
outgrowth and branching were increased (23). Addition of rab-
bit apoE (structurally similar to human apoE3) together with
the b-VLDL reduced neurite branching but very significantly
increased neurite extension (23). In an extension of these
studies, we found that human apoE3 and apoE4, when added
together with b-VLDL, have differential effects on the out-
growth of neurites from DRG neurons in culture (24). Com-
pared with cells incubated with b-VLDL alone, cells treated
with human apoE3 plus b-VLDL showed decreased branching
and increased neurite extension, whereas cells treated with
apoE4 plus b-VLDL had decreased neurite outgrowth (24).
Similar observations showing an isoform-specific effect of ex-
ogenous apoE3 and apoE4 in the presence of a source of lipid
have been described using a murine neuroblastoma cell line
(Neuro-2a) in culture (25).
In the present studies, we stably transfected the Neuro-2a
cells with human apoE3 or apoE4 cDNA and then examined
the effect of endogenously produced apoE on neurite outgrowth.
When incubated with b-VLDL, VLDL, or CSF lipoproteins,
these cells, expressing small amounts of endogenous apoE3 and
apoE4, displayed differences in neurite outgrowth. The en-
hanced neurite outgrowth in the apoE3-secreting cells and
inhibition of neurite outgrowth in the apoE4-secreting cells
were abolished by reagents known to block binding and inter-
nalization of apoE-enriched lipoproteins by the heparan sulfate
proteoglycan (HSPG)-LRP pathway (26–28).
EXPERIMENTAL PROCEDURES
Materials—Dimyristoylphosphatidylcholine (DMPC), Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F-12 (F12) (1:1), media sup-
plements (progesterone, putrescine, selenite, and transferrin), sodium
chlorate, heparinase, lactoferrin, triolein, and egg yolk phosphatidyl-
choline (type XI-E) were purchased from Sigma; fetal bovine serum
(FBS) and insulin were from Life Technologies, Inc. Suramin was
from Miles Inc. (FBA Pharmaceuticals, West Haven, CT), and 1,19-
dioctadecyl-3,3,39,39-tetramethylindocarbocyanine (DiI) was from
Molecular Probes Inc. (Eugene, OR). The murine neuroblastoma cell
line (Neuro-2a) was purchased from American Type Culture Collec-
tion (Rockville, MD). Bovine CSF was obtained from Pel-Freez, Inc.
(Fayetteville, AR).
Preparation of Lipoproteins and Liposomes—Rabbit b-VLDL (d ,
1.006 g/ml) were isolated from the plasma of New Zealand White
rabbits fed a high fat, high cholesterol diet for 4 days (29). Rabbit VLDL
(d , 1.006 g/ml) were isolated by ultracentrifugation from fasting
plasma obtained from rabbits fed a normal rabbit chow. The VLDL were
washed once by ultracentrifugation at d 5 1.006 g/ml. Bovine CSF
lipoproteins (d , 1.21 g/ml) were isolated by ultracentrifugation as
described previously (3). They were washed once by recentrifugation
through a solution of d 5 1.21 g/ml. Canine apoE HDLc (d 5 1.006–1.02
g/ml) were isolated by ultracentrifugation and Pevikon electrophoresis
from the plasma of foxhounds fed a semisynthetic diet containing hy-
drogenated coconut oil and cholesterol (30). The b-VLDL were iodinated
by the method of Bilheimer et al. (31), and free iodine was removed by
PD10 column chromatography. The DMPC vesicles were prepared es-
sentially as described previously (32). The DMPC alone (90 mg) or with
the addition of cholesterol (10 mg) was dissolved in benzene and dried
by lyophilization. The lyophilized material was then resuspended in 3
ml of 0.15 M NaCl, 10 mM Tris-Cl, and 1 mM EDTA (pH 7.6) and
sonicated for 30 min at 37 °C using a sonifier cell disrupter (Branson
450, Danbury, CT) equipped with a microtip and full setting at 7 (50
watts) (32). The material was centrifuged for 10 min at 2,000 rpm
(37 °C), and the supernatant was used for additions to cells. The lipid
emulsion A was prepared as described previously (33, 34). Briefly, the
lipids were mixed together in the ratio, 100 mg of triolein and 25 mg
of egg yolk phosphatidylcholine, and then dried under a stream of
nitrogen. The pellet was then resuspended in 5 ml of 10 mM Tris-Cl,
0.1 M KCl, and 1 mM EDTA (pH 8.0) buffer and sonicated as described
previously (34). The material was then centrifuged for 10 min at
2,000 rpm. The composition of the final emulsion was 2.7:1 for trio-
lein/phosphatidylcholine (w/w). The size and morphology of the emul-
sion particles were determined by negative staining electron
microscopy.
Preparation of Expression Vectors—The expression vectors were as-
sembled in the pBSSK plasmid (Stratagene, La Jolla, CA). The con-
structs contained the rat neuron-specific enolase promoter (kindly pro-
vided by Dr. J. G. Sutcliffe, Scripps Clinic and Research Foundation, La
Jolla, CA), which has been previously used to direct neuron-specific
expression of the human amyloid precursor protein and b-galactosidase
in transgenic mice (35, 36). In addition, the construct contained the first
exon (noncoding), the first intron, and the first six bases of the second
exon (prior to the initiation methionine) of the human apoE gene,
followed by the apoE cDNA. The apoE4 construct was identical except
that it also contained the third intron. The noncoding region of the
fourth exon was downstream from the cDNA, followed by 112 base
pairs of the 39-flanking sequence of the human apoE gene that con-
tains the polyadenylation signal. The apoE constructs for insertion in
these expression vectors were kindly provided by Drs. S. Lauer and J.
Taylor of the J. David Gladstone Institutes. The orientation of the
cDNAs was confirmed by sequencing, using an Applied Biosystems
automated sequencer. The final constructs were referred to as neu-
ron-specific enolase-E3 (for E3 cDNA) and neuron-specific enolase-E4
(for E4 cDNA). Plasmid DNA was purified by two rounds of cesium
chloride gradient ultracentrifugation (37). To test the constructs,
Chinese hamster ovary cells and human embryonic kidney 293 cells
were transiently transfected (lipofectin-mediated), and the concen-
tration of apoE in the medium was measured as described below.
Similar levels of expression of apoE3 and apoE4 were achieved (data
not shown).
Production of Stably Transfected Neuro-2a Cell Lines—Cells at 20–
30% confluence were cotransfected with pSV2 neo and either neuron-
specific enolase-E3 or neuron-specific enolase-E4 using a calcium phos-
phate precipitation protocol (38). Control cells were transfected with
pSV2 neo alone following the same protocol (38). Stably transfected cells
were selected by growth in DMEM/F12 media containing 10% FBS and
400 mg/ml G418 (Geneticin, Life Technologies, Inc.). Individual G418-
resistant colonies were selected and expanded. Secretion of human
apoE3 or apoE4 by the transfected cells was verified by Western blot-
ting of the conditioned media as described below.
Apolipoprotein E Quantitation—Intracellular, cell-surface-bound,
and secreted apoE were quantitated in cells maintained for 96 h in N2
medium, a serum- and lipid-free medium (DMEM/F12 containing
growth supplements (39) with or without added b-VLDL (40 mg of
cholesterol/ml)). The medium was changed once at 48 h. The secreted
apoE reported is that present in the medium following the second 48-h
incubation. The media were collected and, after the addition of protease
inhibitors, centrifuged to eliminate suspended cells. The cell monolay-
ers were washed with PBS and incubated for 1 h at 4 °C with 2 ml of
DMEM/F12 containing 25 mM Hepes and 10 mM suramin, a polyanion
that is able to release apoE bound to the cell surface (27). The apoE was
precipitated from the medium and the suramin extract by addition of 50
mg/ml of fumed silica (Sigma) and centrifugation at 13,000 3 g for 10
min.
Each pellet was washed 3 times with sterile water and dissolved in
gel-loading buffer. Cellular apoE was extracted from the cells, following
suramin removal of surface-bound apoE, using STEN buffer (50 mM
Tris-Cl, pH 7.6, containing 150 mM NaCl, 2 mM EDTA, 1% Nonidet
P-40, 20 mM phenylmethylsulfonyl fluoride, and 5 mg/ml leupeptin).
Samples were electrophoresed on 5–20% polyacrylamide gradient gels
containing sodium dodecyl sulfate, as described previously (40). The
proteins were transferred to nitrocellulose paper by blotting and
treated with an anti-human apoE polyclonal antiserum (1:1,000 dilu-
tion) raised in rabbit (generously provided by Dr. K. H. Weisgraber,
Gladstone Institutes). The nitrocellulose immunoblot then was incu-
bated with donkey anti-rabbit secondary antibody conjugated to horse-
radish peroxidase (1:5,000 dilution) (Amersham Corp.). After washing
to remove unbound antibody, the immunocomplex was detected using
an ECL kit (Amersham Corp.), according to the manufacturer’s instruc-
tions. Quantitation of the level of apoE bound, internalized, and se-
creted by the cells was accomplished by densitometric scanning (Ambis
Scanner, San Diego, CA) and based on a standard curve of purified
human plasma apoE3 and apoE4.
Neurite Outgrowth—Cells were grown in DMEM/F12 containing 10%
FBS and G418 (400 mg/ml). On the day the experiment was initiated,
the cells were subcultured into 35-mm plates in DMEM/F12 with 10%
FBS. The cells were allowed to adhere to the plastic plates for 2 h at
37 °C, and then the culture medium was changed to N2 medium with or
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without increasing concentrations of lipoproteins. After 48 h at 37 °C,
the media were replaced with the same medium (with or without
lipoproteins), and the incubation was continued for an additional 48 h.
(The CSF lipoproteins were dialyzed against N2 medium prior to
addition to the cells.) The cells then were washed with DMEM/F12
containing 0.2% bovine serum albumin, nonspecifically stained for 1
h at 37 °C with DiI added in Me2SO as described previously (24), and
fixed with 2.5% glutaraldehyde in PBS (v/v). Neurons were imaged in
fluorescence mode with a confocal laser scanning system (MRC-600,
Bio-Rad), and the images were digitized with an Image-1/AT image
analysis system (Universal Images, West Chester, PA). The neuronal
images were coded before characterization, and the following vari-
ables were measured: 1) number of neurites (defined as cell surface
projections at least one-half the cell diameter) on each neuron; 2)
neurite branching (the number of branch points on each neurite); and
3) neurite extension (the length of the longest neurite, measured from
the cell body). Typically, in each experiment the neurites of 20–40
neurons/plate were measured, and the results were presented as the
mean 6 S.E.
In studies on the effect of the inhibitors of lipoprotein binding to the
LRP, cells were incubated for 1 h at 37 °C in N2 medium containing the
indicated concentrations of either lactoferrin, chlorate, or heparinase or
with the receptor-associated protein (RAP). Then the b-VLDL were
added, and the incubation was continued for a total of 96 h. The
reagents, except for b-VLDL, were re-added every 24 h. The media and
b-VLDL were replaced after 48 h.
Cell Association and Degradation of 125I-b-VLDL—The cells were
grown for 24 h in 35-mm dishes in N2 medium alone. Then 125I-b-VLDL
(3 mg of protein/ml of medium) were added, and the incubation was
continued for 16 h at 37 °C. The medium was analyzed for trichloroace-
tic acid-soluble lipoprotein degradation products as described previ-
ously (41). The cells were placed on ice, washed with PBS containing
0.2% bovine serum albumin, and dissolved in 0.1 N NaOH. Lipoprotein
cell association was determined by measuring cellular radioactivity
using a g counter (Beckman Gamma 8000, Beckmann Instruments,
Fullerton, CA) (41).
Cell Association of DiI-labeled b-VLDL—The cells were grown for 24
h in 35-mm dishes in N2 medium. Then DiI-labeled b-VLDL (4 mg of
protein/ml of medium), prepared as described previously (42, 43), were
added, and the incubation was continued for 5 h at 37 °C. The cells then
were washed with PBS and fixed with 4% paraformaldehyde in PBS
(v/v). Uptake of DiI-labeled b-VLDL was visualized by fluorescence
microscopy. To quantitate the amount of DiI-labeled lipoprotein in the
cells at the end of the incubation, the cells were scraped, using two
0.5-ml aliquots of PBS, and lyophilized. The DiI was extracted from the
dried cell pellet with methanol and analyzed using a spectrofluorometer
(excitation 520 nm, emission 570 nm) (42). Standards of DiI in methanol
were used for quantitation.
Association of ApoE with Lipid Particles—Apolipoproteins E3 and E4
were iodinated using Bolton-Hunter reagent (DuPont NEN) as de-
scribed previously (44) and then incubated with the lipid particles for 1
h at 37 °C. The samples then were fractionated by chromatography on
a Superose 6 column (10/30 HR, Pharmacia Biotech Inc.) and eluted
with 1 mM EDTA in PBS at a constant flow rate of 0.5 ml/min. Fractions
of 0.5 ml were collected and analyzed for cholesterol and triglyceride,
and the 125I-apoE content was measured in a Beckmann 8000 counter
(Beckmann Instruments) (45).
Statistical Analysis—Data were analyzed using a paired t-test.
RESULTS
The levels of apoE secreted into the medium, bound to the
cell surface, and accumulating intracellularly by the stably
transfected Neuro-2a cells expressing human apoE3 or apoE4
were assessed by Western blot analysis and quantitated by
densitometry (Table I). The cells secreted 44–54 ng of apoE3
and 60–89 ng of apoE4/mg of cell protein in 48 h. The apoE3-
and apoE4-secreting cells had similar amounts of apoE bound
to the cell surface (releasable by suramin treatment), ranging
from 4.9 to 8.0 ng of apoE/mg of cell protein. The intracellular
content of apoE in the two apoE3-expressing cell lines was 140
and 259 ng of apoE/mg of cell protein. Similar amounts of
intracellular apoE (111–215 ng/mg) were seen in the apoE4-
expressing cell lines. The addition of b-VLDL to the cells did
not have a significant effect on the amount of apoE secreted,
surface-bound, or present within the apoE3- or apoE4-secreting
cells (Table I).
In initial experiments, two Neuro-2a cell lines that secreted
similar amounts of apoE3 (clone 1, 54 ng/mg of cell protein) and
apoE4 (clone 4, 60 ng/mg of cell protein) (Table I) were used to
examine the growth of neurites. When these cells were grown
in N2 medium in the absence of b-VLDL, there were no appar-
ent differences in neurite outgrowth between the apoE3- and
apoE4-secreting cells. However, incubation of the cells in N2
medium containing b-VLDL resulted in a markedly different
pattern in the outgrowth of neurites from these cells. Apoli-
poprotein E3-secreting cells incubated with b-VLDL developed
long neurites (Fig. 1A), whereas in apoE4-secreting cells, neu-
rite outgrowth was suppressed (Fig. 1B).
Differences in neurite outgrowth in the absence and presence
of increasing concentrations of b-VLDL were quantitated by
measuring the number of neurites per cell, neurite branching,
and neurite extension (Figs. 2, A–C, respectively). The values
for the non-apoE-transfected control cells incubated for 96 h in
N2 medium in the absence of b-VLDL are set at 100%. The
expression of either apoE3 or apoE4 by the transfected
Neuro-2a cells did not influence neurite number, branching, or
extension when the cells were grown in N2 medium in the
absence of added lipoprotein (Figs. 2, A–C). However, as shown
in Fig. 2A, the addition of b-VLDL resulted in an increase in
the number of neurons in the control cells and in the cells
secreting apoE3 (significantly increased at 40 mg of b-VLDL
cholesterol/ml compared with apoE3-secreting cells in N2 me-
dium). On the other hand, in the presence of high concentra-
tions of b-VLDL, the Neuro-2a cells secreting apoE4 showed a
significant reduction in the number of neurites/cell as com-
pared with the apoE4-secreting cells in the N2 medium.
As described previously for DRG cells (23, 24), the addition of
b-VLDL alone resulted in increased branching of neurites. As
shown in Fig. 2B, addition of b-VLDL to the non-apoE-trans-
fected cells resulted in a significant increase in neurite branch-
ing. In addition, at the highest concentration of b-VLDL cho-
lesterol, the apoE3-secreting cells displayed enhanced
branching by comparison with the apoE3-secreting cells grown
in N2 medium alone. In contrast, the apoE4-secreting cells
tended to show decreased branching when incubated with
b-VLDL; however, this decrease did not reach statistical
significance.
Neurite extension was increased in the Neuro-2a cells secret-
ing apoE3 when they were incubated with the highest concen-
TABLE I
ApoE3 or apoE4 secreted, releasable by suramin, or present inside
cells stably transfected with apoE3 or apoE4 cDNA
Transfected cells were incubated for 96 h in medium with or without
b-VLDL (40 mg cholesterol/ml). The medium was changed at 48 h.
Apolipoprotein E secreted in the last 48 h, intracellular, and suramin-
releasable (surface-bound) apoE were quantitated at the end of the 96
h of incubation as described under “Experimental Procedures.” The
data are the mean of two separate determinations. The duplicates did
not differ by more than 12%.
Cells Secreted Releasable Intracellular
ng apoE/mg cell protein
ApoE3-expressing
Clone 1 54 6.2 140
1 b-VLDL 56 7.2 119
Clone 3 44 4.9 259
1 b-VLDL 45 4.3 251
ApoE4-expressing
Clone 4 60 6.7 215
1 b-VLDL 63 5.3 231
Clone 5 69 8.0 135
1 b-VLDL 62 6.5 128
Clone 6 89 5.2 111
1 b-VLDL 87 5.6 105
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trations of b-VLDL. In contrast, in the apoE4-secreting cells,
neurite extension was very significantly suppressed, even at
the lowest concentration of b-VLDL used (Fig. 2C).
The results described in Fig. 2 were based on a comparison of
cells having neuritic outgrowths and did not take into account
those Neuro-2a cells without neuritic extensions. Approxi-
mately 25–30% of the Neuro-2a cells in N2 medium possessed
neurite extensions (defined as a cell-surface projection of at
least one-half the cell diameter). However, as shown in Fig. 3,
it was apparent that in the presence of b-VLDL, the number of
apoE3-secreting cells developing neurites increased markedly
to 60–70% of the total. On the other hand, the number of
apoE4-secreting cells developing neuritic extensions was sig-
nificantly reduced, compared with the control or apoE3-secret-
ing cells. Thus, the apoE3-secreting cells incubated with
b-VLDL not only had longer neuritic extensions but also
showed an increase in the number of cells with neurites. The
apoE4-secreting cells grown in the presence of b-VLDL showed
fewer neurites, and those that were produced were much
shorter.
To ensure that the differential effect of b-VLDL on neurite
outgrowth in the apoE3- and apoE4-secreting cells was not due
to clonal variation or to differences in the secretion or intracel-
lular content of apoE in the various cell lines, additional ex-
periments were performed with the other stably transfected
cell lines secreting apoE3 or apoE4. Incubation of these cells
FIG. 1. Photomicrographs of representative Neuro-2a cells sta-
bly transfected with apoE3 (A) or apoE4 (B) cDNA and grown for
96 h in N2 medium containing b-VLDL (40 mg of cholesterol/ml).
FIG. 2. Effect of b-VLDL on the number of neurites/cell (A),
neurite branching (B), and neurite extension (C) from control
Neuro-2a cells and from cells stably transfected to express
apoE3 or apoE4. Cells (clone 1 for apoE3-expressing and clone 4 for
apoE4-expressing) were incubated for 96 h in N2 medium alone or in
medium containing increasing concentrations of b-VLDL. The media
were changed at 48 h. The cells were stained with DiI and fixed, and the
indicated parameters were measured. Each data point was obtained by
the measurement of 20–50 cells expressing neurites in four separate
experiments. The data are presented as the percentage of the value
obtained with control cells with N2 medium alone. The data are the
mean 6 the S.E. The average values obtained with control cells incu-
bated with N2 medium alone were as follows: A, neurites/cell 5 3; B,
branch points/neurite 5 2; C, average neurite length 5 155 mm. For
calculation of the level of significance for the effect of added b-VLDL,
the results in the presence of b-VLDL are compared with the data
obtained with the same cells in the absence of b-VLDL (i.e. grown in N2
medium alone). *, p , 0.025; **, p , 0.010; ***, p , 0.005
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with b-VLDL also resulted in differential effects of apoE3 and
apoE4 on neurite outgrowth. As summarized in Table II, in the
presence of b-VLDL, all of the apoE4-secreting cells showed a
significant reduction in the number of neurites expressed,
branching, and neurite extension, whereas the apoE3-secreting
cells displayed an increased number of neurites, increased
branching, and increased extension as compared with cells
grown in N2 medium lacking a source of lipoprotein.
To determine whether apoE4 blocks neurite extension in the
presence of b-VLDL or whether it induces neurite retraction,
the cells were incubated for 48 h in N2 medium alone to
stimulate neurite outgrowth. The medium then was changed,
and the cells were incubated for an additional 48 or 96 h in
media containing b-VLDL (40 mg of cholesterol per ml). The
addition of b-VLDL did not decrease the extension of neurites
of apoE4-expressing cells compared with cells incubated in N2
medium alone (data not shown). Therefore, it appears that
apoE4 in the presence of b-VLDL inhibits neurite extension
directly and does not cause a retraction of neurites that have
already extended.
Other lipoproteins were used to determine if any lipid vehicle
carrying apoE would substitute for b-VLDL. Incubation of the
apoE3- or apoE4-expressing cells with rabbit VLDL, a lipopro-
tein rich in triglyceride, resulted in similar effects on neurite
extension as obtained with b-VLDL. As shown in Table III,
when the Neuro-2a cells secreting apoE3 were incubated with
VLDL, they showed an increase in neurite extension, whereas
the apoE4-secreting cells in the presence of VLDL showed an
inhibition of neurite extension. In other experiments, human
LDL and canine apoE HDLc, an apoE-enriched plasma HDL
induced by cholesterol feeding and resembling apoE-contain-
ing lipoproteins in the CSF (3), also were used. The apoE3-
and apoE4-secreting Neuro-2a cells did not respond to LDL
(40 mg of cholesterol/ml) (i.e. there was no difference in neu-
rite extension as compared with control cells grown in N2
medium alone (data not shown)). On the other hand, incuba-
tion of apoE HDLc (40 mg of cholesterol/ml) with the apoE4-
secreting or apoE3-secreting cells resulted in only a small
reduction or increase in neurite extension, respectively (con-
trol cells in N2 medium, 100%; apoE4-secreting cells plus
HDLc, 85–90% of the value obtained with N2 medium; apoE3-
secreting cells plus HDLc, 110% of the value obtained with
N2 medium).
Liposomes and lipid emulsions also were used in an attempt
to define the type of lipid vehicle required for the delivery of the
apoE. The DMPC emulsion alone or DMPC complexed with
cholesterol were incubated with the apoE3- and apoE4-secret-
ing cells for 96 h at increasing phospholipid concentrations of
up to 45 mg of phospholipid and 5 mg of cholesterol/ml of
medium (higher concentrations were toxic to the cells). In these
studies, there was no effect on neurite outgrowth with either of
the apoE-transfected Neuro-2a cells (data not shown). Previ-
ously, we have shown that apoE complexes with DMPC and
mediates high affinity binding to the LDL receptor (46). On the
other hand, a lipid emulsion particle (emulsion A in Table III),
which was a triglyceride- and phospholipid-containing spheri-
cal particle (;35.8 nm), caused a significant enhancement of
neurite extension in the apoE3-secreting cells and was associ-
ated with an inhibition of outgrowth in the apoE4-secreting
cells.Thus, specific combinations of lipids and/or a unique par-
ticle size may be required to elicit the apoE isoform-specific
effects on neurite outgrowth. It is interesting to note that the
delivery of cholesterol to the cells does not appear to be re-
quired for the differential effect.
Additional studies using the lipoproteins from bovine CSF
suggest that natural lipoproteins in the central nervous system
may mediate the isoform-specific effects of apoE3 and apoE4.
As shown in Fig. 4, addition of lipoproteins isolated from CSF
(d , 1.21 g/ml) to the cells caused an inhibition of neurite
outgrowth from the apoE4-expressing cells and an increase in
outgrowth from the apoE3-expressing cells. When CSF lipopro-
teins were used at a concentration of 40 mg of lipoprotein
cholesterol/ml, the effect was similar to that obtained using
b-VLDL at the same concentration.
Cerebrospinal fluid lipoproteins (d , 1.21 g/ml) were ana-
lyzed for protein and cholesterol content and apolipoprotein
composition. The ratio of cholesterol to protein was approxi-
mately 1:1, similar to data reported for canine CSF (3). The
bovine CSF lipoproteins (d , 1.21 g/ml) contained only apoE
and apoA-I when separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and visualized by Coomassie
Brilliant Blue staining. These results are similar to those
reported previously for human and canine CSF lipoproteins
(3, 47).
The ability of the neuroblastoma cells to bind, internalize,
and degrade b-VLDL was examined to determine whether the
TABLE II
Effect of b-VLDL (40 mg cholesterol/ml of medium) on the number of
neurites/cell, neurite branching, and neurite extension from cells
stably transfected with apoE3 or apoE4
The level of secretion of apoE by clones 1, 3, 4, 5, and 6 is described
in Table I. Clone 2 secreted 36 ng of apoE3/mg of cell protein/48 h.
Surface-bound and internalized apoE was not quantitated for clone 2.
The conditions for incubation with b-VLDL are as described in the
legend to Fig. 2. Each data point was obtained by the measurement of
25–40 cells. The data are the mean 6 S.E. All values are percent of
values obtained with control cells in N2 medium alone.
Cell type No. of neurites Branching Extension
ApoE3-expressing
Clone 1 165 6 30 186 6 39 186 6 13
Clone 2 150 6 25 180 6 15 190 6 23
Clone 3 170 6 39 175 6 20 180 6 25
Apo E4-
expressing
Clone 4 43 6 25 65 6 26 41 6 9
Clone 5 49 6 15 70 6 31 50 6 15
Clone 6 53 6 19 60 6 25 45 6 19
FIG. 3. Effect of b-VLDL on the percentage of cells expressing
neurites. The cells were incubated as described in Fig. 2. Four different
fields in each dish were selected, and the percentage of cells displaying
neurites was measured. Data are the means of three different experi-
ments performed in duplicate (6 S.E.). The percentages of cells express-
ing neurites in the absence of b-VLDL were as follows: control cells
(Control), 35 6 11; apoE3-expressing cells (ApoE3), 32 6 9; apoE4-
expressing cells (ApoE4), 25 6 13. *, p , 0.025 versus control; **, p ,
0.005 versus control
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differences in neurite outgrowth in the apoE3- and apoE4-
expressing cells were due to a different ability of the secreted
apoE3 and apoE4 to stimulate the delivery of apoE and/or
lipoprotein lipids to the cells. In these studies, 125I-b-VLDL
were used to quantitate the binding, uptake, and degradation
of the lipoproteins in the Neuro-2a cells (Table IV). The total
amount of cell-associated (bound and internalized) 125I-b-
VLDL was very similar in the apoE3- and apoE4-secreting
cells (both were slightly lower than that seen in the non-
apoE-transfected control cells). The degradation of 125I-b-
VLDL by the apoE3- and apoE4-secreting cells was similar.
There was a small (but statistically significant) decrease in
the degradation of 125I-b-VLDL by the apoE4-secreting cells
when compared with the non-apoE-transfected control
Neuro-2a cells.
In a parallel experiment, the cells were incubated with DiI-
labeled b-VLDL to visualize the internalization of the lipopro-
teins in the apoE3- and apoE4-secreting cells by fluorescence
microscopy. Following internalization, DiI is trapped in the
lysosomes, and the fluorescent intensity of the cells, therefore,
is proportional to the total amount of lipoprotein internalized
and degraded (42). In these studies, no difference in the uptake
of DiI-labeled b-VLDL was observed in the apoE3- and apoE4-
secreting cells. Extraction and quantitation of the DiI from
cells incubated with DiI-labeled b-VLDL (40 mg of cholesterol/
ml) for 16 h at 37 °C confirmed the visual impression that the
uptake of DiI-labeled b-VLDL was similar in the apoE3- and
apoE4-secreting cells. The control cells incorporated 8.9 6 0.4
ng of DiI/mg of cell protein, while the apoE3- and apoE4-
expressing cells incorporated 10.2 6 1.0 and 10.8 6 0.3 ng of
DiI/mg of cell protein, respectively.
To demonstrate that apoE binds to the lipid particles when it
is present at the concentrations secreted by the cells, we incu-
bated radiolabeled apoE3 or apoE4 with the b-VLDL, VLDL, or
emulsion A for 1 h at 37 °C (100 ng of apoE with 40 mg of
b-VLDL cholesterol or 100 ng of apoE with either 5 mg of VLDL
or emulsion A triglyceride) and fractionated them by FPLC.
Approximately 70% of the apoE was associated with the
b-VLDL and 50% with the VLDL and emulsion A. There was no
difference in the amount of apoE3 or apoE4 associated with the
lipid particles.
To determine which receptor was involved in mediating the
differential effects of apoE3 and apoE4 on neurite outgrowth,
we used inhibitors that block the binding and internalization of
apoE-enriched lipoproteins by the HSPGzLRP pathway, but not
by the LDL receptor pathway, and determined the effect on
neurite outgrowth. Prior to the addition of b-VLDL, the cells
were preincubated for 1 h with either heparinase (20 units/ml)
and chlorate (20 mM), with the RAP (5 mg/ml), or with lacto-
ferrin (10 mg/ml). The binding of apoE-enriched lipoproteins to
the LRP requires their initial binding to cell-surface HSPG.
Heparinase and chlorate cleave and reduce the sulfation of
cell-surface HSPG, respectively (28, 48). Lactoferrin blocks
binding of lipoproteins to both HSPG and LRP, whereas RAP
primarily blocks the binding of apoE-enriched lipoproteins to
the LRP. All of these reagents previously have been shown to
inhibit the uptake of apoE-enriched b-VLDL by the LRP (26,
28, 49, 50). As previously shown in Fig. 2, b-VLDL alone stim-
TABLE IV
Cell association and degradation of 125I-b-VLDL by stably
transfected and control Neuro-2a cells
Cells were incubated for 24 h in N2 medium alone. The 125I-b-VLDL
(3 mg of protein/ml of medium) were then added, and after 16 h at 37 °C
the lipoprotein cell association (bound and internalized) and degrada-
tion by Neuro-2a cells were measured. The data reported are the mean
of two separate experiments performed in duplicate (6 S.D.). Control,
cells transfected with pSV2 neo alone.
Cell type
125I-b-VLDL
Cell association Degradation
ng lipoprotein protein/mg cell protein
Control cells 750 6 16 2,467 6 331
ApoE3-expressing cells 671 6 40a 1,945 6 219
ApoE4-expressing cells 662 6 50a 1,788 6 188b
a p , 0.05 versus control.
b p , 0.01 versus control.
TABLE III
Effect of b-VLDL, VLDL, or lipid emulsions on neurite extension from cells stably transfected with apoE3 or apoE4 cDNA
Cells (clone 1 for apoE3-expressing and clone 4 for apoE4-expressing) were incubated for 96 h in N2 medium alone or containing the indicated
concentrations of particles: b-VLDL, 40 mg of cholesterol/ml of medium (this corresponds to 5 mg of triglyceride/ml of medium); VLDL, 5 mg of
triglyceride/ml of medium; emulsion A, 5 mg of triglyceride/ml of medium. CHOL, cholesterol; TG, triglyceride; PL, phospholipid. Each data point
was obtained by the measurement of 30–40 cells expressing neurites in three separate experiments. The data are the mean 6 S.E.
Treatment Lipid composition Mean size
Value obtained with control cells in N2 medium alone
Control ApoE3-expressing
ApoE4-
expressing
w/w/t nm 6 S.D.
N2 alone 100 6 10 110 6 15 115 6 11
b-VLDL CHOL/TG/PL (5.6:0.4:1) 43.7 6 25.6 120 6 15 160 6 18a 60 6 13a
VLDL CHOL/TG/PL (1:7.4:1) 39.5 6 18.7 110 6 11 155 6 21a 61 6 19a
Emulsion A TG/PL (2.7:1) 35.8 6 14.9 95 6 14 150 6 12a 75 6 12a
a p , 0.010 versus control.
FIG. 4. Effect of CSF lipoproteins on neurite extension from
Neuro-2a cells stably transfected to express apoE3 or apoE4.
Cells were incubated with b-VLDL or bovine CSF lipoproteins (d , 1.21
g/ml) under the conditions described in the legend to Fig. 2. Each data
point represents the measurement of 20–40 neurons. The data are
reported as the mean 6 S.E. The calculation of the level of significance
of the differences observed was performed as described in the legend to
Fig. 2. *, p , 0.025; **, p , 0.01; ***, p , 0.005
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ulated the outgrowth of neurites. The stimulation of neurite
outgrowth by b-VLDL was further enhanced in the apoE3-
expressing cells and markedly inhibited in the apoE4-secreting
cells (Fig. 2 and Table V). The addition of chlorate and hepa-
rinase or RAP did not block the stimulatory effect of b-VLDL on
neurite outgrowth in the control cells (Neuro-2a cells not ex-
pressing apoE), suggesting that the effect of b-VLDL alone is
mediated by the LDL receptor; however, these reagents blocked
the isoform-specific effects in the cells secreting apoE (Table V).
Chlorate and heparinase treatment of the cells or the addition
of RAP prevented the stimulation of neurite extension in the
apoE3-expressing cells incubated with b-VLDL (that is, signif-
icantly decreased the b-VLDL-induced neurite extension in the
Neuro-2a cells secreting apoE3). Moreover, chlorate and hepa-
rinase or RAP blocked the inhibition of neurite extension seen
in the apoE4-expressing cells (that is, the apoE4-expressing
cells in the presence of b-VLDL did not demonstrate inhibition
of neurite extension but, in fact, showed increased extension)
(Table V). In the presence of heparinase and chlorate or RAP,
in the apoE-secreting cells, neurite outgrowth was similar to
that observed when b-VLDL were added to the control cells in
the absence of apoE (Table V). Therefore, in the presence of
these reagents, the LDL receptor-mediated effect of b-VLDL
was not blocked. Lactoferrin also blocked the effects of apoE3
and apoE4 on neurite outgrowth; however, it also slightly sup-
pressed the effect of b-VLDL on neurite extension in the control
cells. These data show that inhibition of the interaction be-
tween b-VLDL and the HSPGzLRP pathway prevents the dif-
ferential effects of apoE3 and apoE4 on neurite outgrowth
(Table V).
DISCUSSION
We have previously shown that human apoE3 and apoE4
have a differential effect on the outgrowth of neurites from
DRG neurons and Neuro-2a cells in culture when added exog-
enously to the cells together with b-VLDL (23–25). Compared
with cells treated with b-VLDL alone, cells incubated with
b-VLDL and apoE3 had decreased neurite branching and in-
creased neurite extension, whereas cells incubated with apoE4
and b-VLDL showed a decrease in both neurite branching and
extension (24). In the current studies, we have demonstrated
that in the presence of b-VLDL, VLDL, CSF lipoproteins, or
specific lipid emulsions (containing triglyceride and phospho-
lipid), the endogenous synthesis and secretion of nanogram
quantities of apoE3 and apoE4 by transfected murine neuro-
blastoma cells (Neuro-2a) had differential effects on neurite
outgrowth. Stably transfected cells secreting comparable
amounts of human apoE3 or apoE4 display similar patterns of
neurite outgrowth when incubated in the absence of lipopro-
teins. However, the addition of as little as 5–10 mg of b-VLDL
cholesterol/ml of medium or 5 mg of VLDL triglyceride/ml of
medium caused a dramatic difference in the neurite extension
and branching in the apoE3- and apoE4-secreting cells.
Whereas both branching and extension were increased in the
apoE3-producing cells, these processes were very significantly
inhibited in the apoE4-producing cells. This differential effect
was not due to clonal variation, because similar results were
obtained using several different stably transfected lines that
secreted different levels of apoE. The inhibitory effect on neu-
rite outgrowth in the apoE4-secreting cells was dependent
upon the presence of a source of lipid during the initiation of
neurite formation, since b-VLDL added to apoE4-secreting
cells after the neurites had already formed did not result in
neurite retraction.
It has been shown that the addition of a lipid source (b-
VLDL, VLDL, CSF lipoproteins, apoE-containing HDL, or spe-
cific lipid emulsions) to the apoE3- and apoE4-secreting cells is
necessary for the isoform-specific effect on neurite outgrowth to
occur. This pathway may involve a secretion-capture role for
apoE, as has been postulated to occur with other cell types
secreting apoE (1, 6, 27). We have shown that the apoE se-
creted by the transfected Neuro-2a cells interacts with the
lipoproteins in the medium. In addition, the apoE may interact
with cell-surface HSPG and, by either or both of these pro-
cesses, may mediate lipoprotein or lipid emulsion uptake by the
LDL receptor or the LRP (1, 26, 27, 51). Our data demonstrate
that it is the HSPGzLRP pathway that is important for the
differential effects of apoE3 and apoE4 on neurite outgrowth.
These data are consistent with the studies of Holtzman et al.
(52), in which the addition of RAP and anti-LRP antibody
blocked the stimulatory effect of apoE3 on NGF-induced neu-
rite extension in an immortalized central nervous system-de-
rived neuronal cell line in culture. The data also support a role
for the LDL receptor in mediating the stimulatory effect of
b-VLDL alone on neurite outgrowth. The VLDL receptor that
also binds apoE-containing lipoproteins and could be involved
in mediating the uptake of the b-VLDL is not present in the
Neuro-2a cells.2
It has been shown previously that apoE-enriched lipopro-
teins bind initially to cell-surface HSPG and are then trans-
ferred to LRP prior to internalization or that the HSPGzLRP
complex itself is internalized by the cells (1, 6, 26–28). Lipid-
2 B. P. Nathan, S. Bellosta, R. W. Mahley, and R. E. Pitas, unpub-
lished results.
TABLE V
Effect of chlorate, heparinase, RAP, and lactoferrin in the presence of b-VLDL on neurite extension from cells stably transfected with
apoE3 or apoE4 cDNA
Cells were incubated for 1 h in N2 medium alone or containing the indicated concentrations of chlorate, heparinase, RAP, or lactoferrin. Then
the b-VLDL were added, and the incubation was continued for a total of 96 h. The reagents, except for b-VLDL, were readded every 24 h. The media
and b-VLDL were changed at 48 h. Each data point was obtained by measuring 30–40 neurons expressing neurites in two separate experiments.
Data are the mean 6 S.E. Values are percent of values obtained with control cells in N2 medium alone.
Treatment Control ApoE3-expressing ApoE4-expressing
N2 alone 100 6 8 105 6 10 103 6 9
b-VLDL (40 mg cholesterol/ml) 160 6 13 209 6 13a 70 6 4b
b-VLDL 1 chlorate (20 mM) and
heparinase (20 units/ml)
159 6 14 163 6 20c 138 6 12d
b-VLDL 1 RAP (5 mg/ml)e 176 6 11 179 6 15 160 6 16d
b-VLDL 1 lactoferrin (10 mg/ml) 128 6 16 154 6 19c 130 6 12d
a p , 0.05 versus value obtained with control cells (non-apoE-expressing cells incubated with b-VLDL).
b p , 0.01 versus value obtained with control cells (non-apoE-expressing cells incubated with b-VLDL).
c p , 0.05 versus apoE3-expressing cells with b-VLDL alone.
d p , 0.01 versus apoE4-expressing cells with b-VLDL alone.
e In a parallel set of experiments, 5 mg/ml of RAP did not block the binding of DiI-labeled LDL to the Neuro-2a cells.
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free apoE is a poor ligand for any of the lipoprotein receptors,
including the LRP. Thus, a specific lipoprotein vehicle (e.g.
b-VLDL, VLDL, CSF lipoproteins, specific lipid emulsions, or
apoE-containing HDL), capable of being enriched in apoE, may
be required to target apoE3 and apoE4 into a specific intracel-
lular pathway to allow for the differential effects of the apoE
isoforms. Once they are internalized, it is necessary to postu-
late that the apoE isoforms are handled differently by the cells
in such a way that apoE3 has a stimulatory role and apoE4 has
an inhibitory role in regulating neurite outgrowth.
There are several lines of evidence suggesting that the dif-
ferential effects of the apoE isoforms on neurite outgrowth are
secondary to an effect on the cytoskeleton, possibly by modu-
lating microtubular assembly. In Neuro-2a cells, the addition of
exogenous apoE3 plus b-VLDL results in an abundance of well
formed microtubules in the presence of neurite extension,
whereas cells incubated with apoE4 and b-VLDL primarily
contain monomeric tubulin, and neurite outgrowth is impaired
(25). In vitro biochemical studies have shown that apoE3 inter-
acts avidly with the microtubular-associated proteins t and
MAP 2C, whereas apoE4 does not (53, 54). It has been postu-
lated that apoE3 facilitates the ability of t and MAP 2C to
interact with and stabilize microtubules. These observations
suggest one possible mechanism whereby apoE3 may be pro-
tective in preventing late onset AD and apoE4 may be detri-
mental (55, 56). If this is, in fact, the mechanism by which
apoE3 and apoE4 affect neurite outgrowth, the question re-
mains as to whether it is a direct or indirect effect of apoE on
the cytoskeleton. If it is a direct effect, apoE must escape
intracellular endosomes and enter the cytoplasm by an un-
known mechanism. It has been suggested that apoE may
occur in the cytoplasm (57). Alternatively, apoE3 and apoE4
may have an indirect effect on the cytoskeleton and signal
changes in activity that support or suppress extension. This
could occur following internalization of the apoE or through
differential signaling events induced by apoE3 and apoE4
following binding to the HSPGzLRP on the cell surface. In-
terpretation of these data remains speculative at the present
time.
The b-VLDL and VLDL, which in the presence of apoE3 or
apoE4 give the maximum differential effect on neurite out-
growth in both the current studies and in those previously
reported (23, 24), do not occur in the central nervous system.
The CSF, however, does contain HDL. It has been shown pre-
viously that human and canine CSF contain separate popula-
tions of HDL containing either apoE or apoA-I (3, 47). The
apoE-containing HDL in the CSF are similar to the apoE HDLc
used in our studies that were able to mediate a small inhibitory
effect of apoE4 on neurite outgrowth. Moreover, the addition of
CSF lipoproteins mimicked the effect of the b-VLDL. Thus, the
CSF lipoproteins could serve as vehicles for the delivery of the
apoE3 or apoE4 to neurons.
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